CELC Share Price Performance
US$102.01
91.50 (870.60%)
12.6% undervalued intrinsic discount
US$116.70
Fair Value
Price US$102.01
AnalystConsensusTarget US$116.70
AnalystLowTarget US$94.00
Fair ValueUS$116.70
Share Pricen/a
Celcuity Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
CELC Community Narratives
AN
Fair Value US$116.7 12.6% undervalued intrinsic discount
Future Oncology Approvals And Pipeline Expansion Will Support A Stable Long Term Outlook
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$94 8.5% overvalued intrinsic discount
Single Drug Dependence And Heavy Financing Will Shape A Challenging Future
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Single Drug Dependence And Heavy Financing Will Shape A Challenging Future
Catalysts About Celcuity Celcuity is a clinical stage biotechnology company focused on developing gedatolisib for hormone receptor positive, HER2 negative advanced breast cancer and metastatic castration resistant prostate cancer. What are the underlying business or industry changes driving this perspective?Read more
2
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$94
8.5% overvalued intrinsic discount
Fair Value
Profit Margin
31.31%
Future PE
50.55x
Price in 2029
US$0
Future Oncology Approvals And Pipeline Expansion Will Support A Stable Long Term Outlook
Catalysts About Celcuity Celcuity is a clinical stage biotechnology company focused on developing gedatolisib for hormone receptor positive, HER2 negative advanced breast cancer and metastatic castration resistant prostate cancer. What are the underlying business or industry changes driving this perspective?Read more
36
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$116.7
12.6% undervalued intrinsic discount
Fair Value
Profit Margin
25.1%
Future PE
53.44x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
Single Drug Dependence And Heavy Financing Will Shape A Challenging Future
Fair Value: US$94 8.5% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Future Oncology Approvals And Pipeline Expansion Will Support A Stable Long Term Outlook
Fair Value: US$116.7 12.6% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Celcuity Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Mar 25, 2026
- -3.52
- 0%
- 0%
- 273.8%
About CELC
- Founded
- 2011
- Employees
- 87
- CEO
- WebsiteView website
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company’s lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). It also engages in developing of CELsignia diagnostic platform. The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota.
